StreetInsider.com News Articles

UBS Starts Solid Biosciences (SLDB) at Buy

Wed, 14 Oct 2026 16:45:41 -0400

UBS initiates coverage on Solid Biosciences (NASDAQ: SLDB) with a Buy rating and a price target of $20.00.

For an analyst ratings summary and ratings history on Solid Biosciences click here. For more ratings news on Solid Biosciences click here.

Shares of Solid Biosciences closed at $5.82 yesterday.

Form 4 Solid Biosciences Inc. For: Oct 02 Filed by: SMITH IAN F

Tue, 06 Oct 2026 16:36:00 -0400

si-local-file:///var/storage/secattach/20261006/27156025.html

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 16:05:00 -0400

CHARLESTOWN, Mass., Oct. 01, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced a grant of 8,150 restricted stock units (“RSUs”) to one newly hired employee.

The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s continued service with the Company through each applicable vesting date.

This grant was made pursuant to

Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 01 Oct 2026 16:05:00 -0400

This grant was made pursuant to

Solid Biosciences (SLDB) Reiterated at Overweight by Cantor Fitzgerald, Stock a 'Top Pick'

Wed, 16 Sep 2026 09:33:27 -0400

(Updated - September 16, 2026 9:33 AM EDT)

Cantor Fitzgerald analyst Kristen Kluska reiterated an Overweight rating and $26.00 price target on Solid Biosciences (NASDAQ: SLDB).

The analyst commented, "SLDB is a Top Pick for us, driven by its differentiated capsid and construct in a highly validated commercial indication, DMD. We'd be buyers ahead of the update and believe shares could more than double on a positive outcome. SLDB's Functional Data will be Comprehensive and SV95C is a Good Endpoint to Mitigate Bias. SLDB is preparing to submit a briefing book to the Agency soon with roughly a dozen patients with data

RBC Capital Starts Solid Biosciences (SLDB) at Outperform

Wed, 16 Sep 2026 05:23:23 -0400

RBC Capital initiates coverage on Solid Biosciences (NASDAQ: SLDB) with a Outperform rating and a price target of $18.00.

For an analyst ratings summary and ratings history on Solid Biosciences click here. For more ratings news on Solid Biosciences click here.

Shares of Solid Biosciences closed at $8.37 yesterday.

H.C. Wainwright Reiterates Buy Rating on Solid Biosciences (SLDB)

Mon, 14 Sep 2026 07:34:12 -0400

H.C. Wainwright analyst Arthur He reiterated a Buy rating and $25.00 price target on Solid Biosciences (NASDAQ: SLDB).

The analyst commented: "On September 9, we hosted an investor dinner with Solid Biosciences management, President and CEO Bo Cumbo, Chief Medical Officer Gabriel Brooks, M.D., and Chief Financial Officer Kevin Tan, to discuss how SGT-003 sets up into a late-4Q26 FDA meeting and how the SGT-212 study is progressing. We came away from the two-hour discussion with higher confidence, and our central takeaway is that the SGT-003 accelerated approval (AA) discussion has been methodically staged rather than improvised. Alongside a Friedreich ataxia

Solid Biosciences to Participate at Upcoming Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

CHARLESTOWN, Mass., Sept. 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company” or “Solid”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced participation in the following investor conferences:

2026 Cantor Global Healthcare Conference
Bo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A live webcast of the presentation will be available by clicking here.

2026 Citi Biopharma Back to School Conference
Mr.

Solid Biosciences to Participate at Upcoming Investor Conferences

Wed, 02 Sep 2026 08:00:00 -0400

2026 Cantor Global Healthcare Conference
Bo Cumbo, President and CEO, and Gabriel Books, M.D., Chief Medical Officer, will participate in a fireside chat on Wednesday, September 9, 2026, at 3:55 p.m. ET. A live webcast of the presentation will be available by clicking here.

2026 Citi Biopharma Back to School Conference
Mr.

Solid Biosciences (SLDB) PT Raised to $26 at Cantor Fitzgerald Before INSPIRE Ph1/2 Readout

Thu, 27 Aug 2026 07:30:24 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Solid Biosciences (NASDAQ: SLDB) to $26.00 (from $16.00) while maintaining an Overweight rating.

The analyst commented, "SLDB has a key upcoming catalyst: the first functional data readout from the Phase 1/2 INSPIRE study of SGT-003 (AAV-based gene therapy) in DMD, expected YE26/Early 27. This readout will be the first opportunity to determine whether SGT-003's differentiated construct and robust biomarker profile translate into functional benefit. Against this backdrop, we benchmark SGT-003 against competing AAVbased gene therapies, RGX-202 (RGNX; NC) and ELEVIDYS (SRPT; N). We believe SGT-003 has the potential to become a

Solid Biosciences (SLDB) PT Raised to $26 at Cantor Fitzgerald Before INSPIRE Ph1/2 Readout

Thu, 27 Aug 2026 07:30:24 -0400

Cantor Fitzgerald analyst Kristen Kluska raised the price target on Solid Biosciences (NASDAQ: SLDB) to $26.00 (from $16.00) while maintaining an Overweight rating.

Truist Securities Assumes Solid Biosciences (SLDB) at Buy

Fri, 21 Aug 2026 05:13:21 -0400

Truist Securities analyst Danielle Bril assumes coverage on Solid Biosciences (NASDAQ: SLDB) with a Buy rating and a price target of $20.00.

For an analyst ratings summary and ratings history on Solid Biosciences click here. For more ratings news on Solid Biosciences click here.

Shares of Solid Biosciences closed at $9.10 yesterday.

Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932875.html

Form SCHEDULE 13D/A Solid Biosciences Inc. Filed by: PERCEPTIVE ADVISORS LLC

Fri, 14 Aug 2026 17:24:00 -0400

si-local-file:///var/storage/secattach/20260814/26932875.html

Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930565.html

Form SCHEDULE 13G/A Solid Biosciences Inc. Filed by: Vestal Point Capital, LP

Fri, 14 Aug 2026 16:15:00 -0400

si-local-file:///var/storage/secattach/20260814/26930565.html

Solid Biosciences (SLDB) Reiterated at Market Outperform by Citizens on Continued Execution

Mon, 10 Aug 2026 04:26:12 -0400

Citizens analyst Silvan Turkcan reiterated a Market Outperform rating and $15.00 price target on Solid Biosciences (NASDAQ: SLDB).

The analyst commented, "Solid Biosciences reported 2Q26 financial results and highlighted continued execution across its genetic medicine pipeline, led by Duchenne muscular dystrophy (DMD) gene therapy SGT-003. The third, and critical, FDA interaction regarding SGT-003 is on track for 4Q26. Meanwhile, SLDB anticipates dosing patients with its third novel gene therapy, SGT-501 indicated for Catecholaminergic polymorphic ventricular tachycardia (CPVT), in 2H26. With more clarity on the route ahead for SGT-003 in DMD coming soon and a more gene Tx-friendly FDA, we maintain our

Solid Biosciences (SLDB) Tops Q2 EPS by 7c

Thu, 06 Aug 2026 17:57:51 -0400

Solid Biosciences (NASDAQ: SLDB) reported Q2 EPS of ($0.38), $0.07 better than the analyst estimate of ($0.45).

For earnings history and earnings-related data on Solid Biosciences (SLDB) click here.

Form 8-K Solid Biosciences Inc. For: Aug 06

Thu, 06 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26885566.html

Form 8-K Solid Biosciences Inc. For: Aug 06

Thu, 06 Aug 2026 17:16:00 -0400

si-local-file:///var/storage/secattach/20260806/26885566.html

Form 424B5 Solid Biosciences Inc.

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885440.html

Form 424B5 Solid Biosciences Inc.

Thu, 06 Aug 2026 17:07:00 -0400

si-local-file:///var/storage/secattach/20260806/26885440.html

Form S-3ASR Solid Biosciences Inc.

Thu, 06 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26885310.html

Form S-3ASR Solid Biosciences Inc.

Thu, 06 Aug 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20260806/26885310.html

Solid Biosciences Reports Second Quarter 2026 Financial Results and Provides Business Updates

Thu, 06 Aug 2026 16:08:00 -0400

- Duchenne (SGT-003): SGT-003 has been generally well tolerated in the Phase 1/2 INSPIRE DUCHENNE clinical trial, with 53 participants dosed as of August 4, 2026 -

- Solid expects to meet with the FDA in late Q4 2026 to discuss the SGT-003 data package and to seek guidance on a potential accelerated approval pathway for SGT-003 -

- Initiation of dosing in the Phase 3 IMPACT DUCHENNE placebo-controlled, randomized, double-blind clinical trial commenced in Q2 2026 -

- Friedreich’s Ataxia (SGT-212): Continued participant screening and enrollment is underway in the Phase 1b FALCON clinical